GlassScriptPhysician profile
Michelle J Winsor
NPI 1467700823
$8,158.67
in general payments reported to CMS, 2019-2025
24 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $1,235 · 2023: $1,891 · 2024: $1,960 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,609 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,609.20 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.59 | 2021-2025 | |
| Genzyme Corporation | $1,137.33 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $719.69 | 2021-2025 | |
| Incyte Corporation | $653.45 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $629.98 | 2021-2025 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $560.05 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $457.43 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $400.51 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $333.70 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $215.77 | 2021-2025 | Adbry |
| Amgen INC. | $201.19 | 2021-2025 | Otezla |
| Ucb, INC. | $196.27 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $186.26 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Vyne Pharmaceuticals INC. | $157.88 | 2021 | |
| Novo Nordisk INC | $142.24 | 2024-2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $122.55 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $114.20 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $76.53 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $66.77 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.80 | 2021-2024 | Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.82 | 2023 | Cyltezo |
| Organon LLC | $20.65 | 2025 | |
| Botanix Sb INC | $16.18 | 2025 | Sofdra |
| Azurity Pharmaceuticals, INC. | $15.83 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Winsor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.